May 2017 PMID 28131725

The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.

Roberto Frau, Paola Savoia, Silvia Fanni, Chiara Fiorentini, Camino Fidalgo, Elisabetta Tronci, Roberto Stancampiano, Mario Meloni, Antonino Cannas, Francesco Marrosu, Marco Bortolato, Paola Devoto, Cristina Missale, Manolo Carta

Full text PDF Download social card

Mentions

Peak: 1 in Jul 2022

across 2 sources since Jul 2022

Extended reach

119,758

potential audience

Total likes

2,810

Video views

119,757

Mentions per month

Jul 2022 – Jun 2025

Where it's discussed

YouTube3 videos
X / Twitter1 posts

AI synopsis

What people are saying

Discussions highlight the study's findings, such as finasteride's ability to reduce dyskinesia without impairing motor functions, and note its potential for broad therapeutic use, with some posts referencing its relevance to neurosteroid synthesis and dopamine receptor activity. The tone varies from cautious optimism to academic interest, reflecting both curiosity and recognition of the research's importance.

AgreementModerate agreement

Most discussions seem to agree that the research presents promising results, with some emphasizing the potential clinical applications.

InterestModerate interest

Participants show moderate interest, with mentions of neurosteroid modulation and Parkinson's disease, indicating curiosity but not overwhelming enthusiasm.

EngagementModerate engagement

Comments include references to the study's methodology and implications, suggesting thoughtful engagement rather than superficial buzz.

ImpactModerate impact

Many recognize the study's potential to influence future treatments, reflecting awareness of its significance in neuropharmacology.

Abstract in brief

The study investigated whether finasteride, a 5alpha reductase inhibitor, can reduce levodopa-induced dyskinesia (LID) in rat models of Parkinson's disease by blocking neurosteroid synthesis, which affects dopamine receptor signaling.
Finasteride was shown to significantly decrease dyskinesias across various doses and treatment protocols without impairing the therapeutic effects of levodopa on motor function, indicating its potential as an anti-dyskinetic agent.
The research also explored whether finasteride's effects involved modulation of dopamine receptor functions and found similar benefits in both male and female rats, suggesting broad applicability for managing LID in Parkinson's patients.]

Read the full abstract

silliböcük ayrani

@gnoppsiffymarf · X

Jun 20, 2025 · 1 followers View post →

The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Finasteride's Role in Reducing Dyskinesia in Parkinson's Disease

Evaluating Finasteride's Impact on Prostate Cancer Outcomes

Strategies to Minimize Finasteride Side Effects for Better Outcomes